ncRNA basic information
ncRNA ID:
ENSG00000249395
ncRNA Database:
Ensembl
ncRNA Name:
CASC9
ncRNA Type:
lncRNA
ncRNA Expression:
up-regulated
ncRNA Method:
RT-PCR
ncRNA Target Gene:
NA
ncRNA Pathway:
NA
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB00997 (APRD00185, DB05331, DB05847)
Drug Name:
Doxorubicin
Drug Method:
The expression of CASC9 in breast cancer tissues and cell lines, in addition to drug-resistant breast cancer cells (MCF-7/DOX), was detected by reverse transcription-quantitative polymerase chain reaction. Subsequently, MCF-7/DOX cells were transfected with the silencing vector pS-CASC9, containing enhancer of zeste homolog 2 (EZH2), multidrug resistance protein 1 (MDR1) or control small interfering (si)RNAs. The viability, apoptosis, migration and invasion of the transfected cells were assessed via an MTT assay, flow cytometry and a Transwell assay, respectively. The expression levels of apoptosis-associated proteins (apoptosis regulator Bcl-2, apoptosis regulator BAX, caspase-3 and caspase-9) were determined by western blotting. An RNA pull-down assay was performed to identify CASC9-binding candidates. In addition, the expression levels of the MDR1 gene and its encoded protein, P-glycoprotein, were detected.
Drug Response:
resistant
Cancer basic information
Cancer:
breast cancer
Tissue/Cell:
cell line (MCF-7/DOX)
Other information
Title:
Long noncoding RNA cancer susceptibility candidate 9 promotes doxorubicin-resistant breast cancer by binding to enhancer of zeste homolog 2.
Journal:
Int J Mol Med
Published:
2018
PubMed ID:
30106089